[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100504085":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":40,"centralContacts":45,"locations":55,"responsibleParty":81,"collaborators":84,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":31,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":96,"maxAge":31,"enrollmentInfo":97,"targetDuration":31,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":57,"whyStopped":31,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Baylor College of Medicine","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"iTCBT-I (Intensive Transdiagnostic Cognitive Behavioral Therapy-Individual)","EXPERIMENTAL","Patients in this arm will receive transdiagnostic CBT delivered in an intensive individual format over 2 weeks. Intensive Transdiagnostic Cognitive Behavior Therapy-Individual (iTCBT-I): Participants randomized to this condition will receive 12 hours of treatment in four 3 hour sessions, over a 2-week period. Treatment consists of psychoeducation, cognitive restructuring, and exposure exercises.\n\nFor treatment non-responders (i.e., BAI score decrease \\\u003C 10), patients will receive 4 additional 90 minute sessions of individual therapy over a 2-week period (iTCBT-Enhanced). These sessions will identify areas where participants might benefit from more in-depth focus on specific concepts taught in the treatment.",[13],"Behavioral: iTCBT-I",{"label":15,"type":16,"description":17,"interventionNames":18},"iTCBT-G (Intensive Transdiagnostic Cognitive Behavioral Therapy-Group)","ACTIVE_COMPARATOR","Patients in this arm will receive transdiagnostic CBT delivered in an intensive group format over 2 weeks. Intensive Transdiagnostic Cognitive Behavior Therapy-Group (iTCBT-G): Participants randomized to this condition will receive 12 hours of treatment over a 2-day period (6 hrs each day). Treatment consists of psychoeducation, cognitive restructuring, and exposure exercises.\n\nFor treatment non-responders (i.e., BAI score decrease \\\u003C 10), patients will receive 4 additional 90 minute sessions of individual therapy over a 2-week period (iTCBT-Enhanced). These sessions will identify areas where participants might benefit from more in-depth focus on specific concepts taught in the treatment.",[19],"Behavioral: iTCBT-G",{"label":21,"type":16,"description":22,"interventionNames":23},"Treatment as Usual (TAU)","Patients in this arm will not receive transdiagnostic CBT but will receive treatment as usual, which may include other forms of psychotherapy and\u002For medication.",[24],"Behavioral: TAU",[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"BEHAVIORAL","iTCBT-I","Individual format over 2 weeks",[9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"iTCBT-G","Group format over 2 days",[15],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"TAU","Standard care",[21],[41],{"name":42,"affiliation":43,"role":44},"Ellen Teng, PhD","Michael E. DeBakey VA Medical Center","PRINCIPAL_INVESTIGATOR",[46,51],{"name":42,"role":47,"phone":48,"phoneExt":49,"email":50},"CONTACT","(713) 791-1414","225513","eteng@bcm.edu",{"name":52,"role":47,"phone":48,"phoneExt":53,"email":54},"Keri Bayley, PhD","226419","Keri.Bayley@bcm.edu",[56],{"facility":43,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"RECRUITING","Houston","Texas","77030","United States","US",{"type":64,"coordinates":65},"Point",[66,67],-95.36327,29.76328,{"lat":67,"lon":66},[70,71,72,75,77,79],{"name":42,"role":47,"phone":48,"phoneExt":49,"email":50},{"name":52,"role":47,"phone":48,"phoneExt":53,"email":54},{"name":73,"role":74,"phone":31,"phoneExt":31,"email":31},"Cynthia Kraus Schuman, PhD","SUB_INVESTIGATOR",{"name":76,"role":74,"phone":31,"phoneExt":31,"email":31},"Nicole Trapp, PhD",{"name":78,"role":74,"phone":31,"phoneExt":31,"email":31},"Terri Fletcher, PhD",{"name":80,"role":74,"phone":31,"phoneExt":31,"email":31},"Caitlin Clark, PhD",{"type":44,"investigatorFullName":82,"investigatorTitle":83,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Ellen Teng","Principal Investigator",[85],{"name":86,"class":87},"United States Department of Defense","FED","100504085","enhancing-psychotherapy-for-veterans-and-service-members-with-ptsd-and-anxiety-100504085",false,"NCT05843695","Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety","Enhancing Intensive Transdiagnostic Cognitive Behavioral Therapy for Veterans With PTSD and Anxiety Disorders","Inclusion Criteria:\n\n* Veteran\u002FService Member at least 18 years old\n* Current diagnosis of at least one anxiety-based disorder: Posttraumatic Stress Disorder, Panic Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder, Other Specified Trauma- and Stressor-Related Disorder, Other Specified Anxiety Disorder, and Unspecified Anxiety Disorder (based on ADIS-5)\n* Moderate-to-poor life enjoyment and satisfaction as indicated by a score of 47 or lower on the QLES-Q-SF\n* Stable on psychotropic medication for 4 weeks before study participation\n* Willing to be randomized to treatment condition\n\nExclusion Criteria:\n\n* Active symptoms of mania or psychosis at baseline (based on ADIS-5)\n* Depression with active suicidal ideation and intent that would preclude treatment (based on ADIS-5 \\& BDI-II)\n* Moderate-to-severe cognitive impairment as indicated by the SLUMS (a score below 20)\n* Veterans\u002FService Members with comorbid substance\u002Falcohol use or dependence are study eligible but must agree to reduce and limit their use of substances during the active course of treatment, particularly during exposure exercises. If they do not agree to this, they will be excluded\n* Undergoing concurrent transdiagnostic CBT specifically targeting any of the above-mentioned disorders","ALL","18 Years",{"count":98,"type":99},306,"ESTIMATED","INTERVENTIONAL",[102],"NA","The goal of this clinical trial is to compare two different intensive formats of delivering cognitive-behavioral treatment for people with PTSD and anxiety disorders. The main questions it aims to answer are:\n\n* Is iTCBT delivered in individual and group formats more effective than TAU in improving anxiety symptoms and quality of life?\n* For treatment non-responders, is iTCBT-Enhanced more effective than TAU improving anxiety symptoms and quality of life?\n* Does iTCBT-Individual produce a larger improvement in anxiety and quality of life compared with iTCBT-Group?\n\nParticipants will undergo several assessments throughout the course of the study. Based on randomization, they will receive: (1) iTCBT in an individual format over a 2-week period, (2) iTCBT in a group format over a 2-day period, or (3) usual care. Those who do not show a response to treatment will receive 4 additional individual therapy sessions.",[105,106],"Posttraumatic Stress Disorder","Anxiety Disorders",[108,109,110,111,112,113],"PTSD","Anxiety","Veterans","Service Members","Reservists","Treatment","2026-01-30",{"date":116,"type":117},"2026-02-03","ACTUAL",{"date":119,"type":117},"2023-09-22",{"date":121,"type":99},"2027-03-30",{"name":5,"class":6},1]